Development Pipeline

Avanti Biosciences is advancing novel therapeutics from discovery through clinical development. Our lead program, ABI-171, is IND-ready and positioned to enter Phase 1 clinical trials in Q3 2026.

​

LEAD PROGRAM: ABI-171 for Idiopathic Pulmonary Fibrosis (IPF)

Status: IND-Ready | Phase 1 Start: Q3 2026

ABI-171 is a novel small-molecule therapeutic candidate for idiopathic pulmonary fibrosis (IPF). The program has achieved IND-ready status with significant regulatory and funding milestones.

Key Milestones:

✓ FDA Orphan Drug Designation granted
✓ FDA Pre-IND Meeting granted (PIND 180251, scheduled Q1 2026)
✓ IND-Ready Status - GLP toxicology complete, GMP manufacturing established
✓ Phase 1 Clinical Trial starting Q3 2026

Market Opportunity: IPF therapeutics market valued at $4.0B (2024), projected to reach $6.9B by 2030.

Recent Validation: In January 2025, Eli Lilly acquired Mediar Therapeutics for $99M upfront for a Phase 1-ready IPF asset, demonstrating strong pharma interest in differentiated IPF therapies.

​

ABI-171 for Liver Fibrosis

Status: Preclinical Development

Avanti is expanding the ABI-171 platform into liver fibrosis, leveraging the validated anti-fibrotic mechanism from our IPF program.

Program Status:

• Preclinical efficacy studies ongoing

• IND filing targeted for 2027-2028

• Development contingent on IPF Phase 1 success

Market Opportunity: Liver fibrosis therapeutics market projected to grow from $2.3B (2023) to $4.5B by 2032. NASH represents a major contributor to liver fibrosis, affecting approximately 6 million US adults with significant fibrosis.

​

Discovery Program for Alzheimer's Disease

Status: Discovery Stage

Our discovery-stage program targets a validated kinase enzyme (DYRK1A) implicated in Alzheimer's disease pathology.

Program Status:

• Discovery stage (lead optimization)

• Estimated timeline to IND: 3-4 years

• Resource dependent

Market Opportunity: Alzheimer's therapeutics market projected to exceed $15B by 2030.

​

Partnership Opportunities

For business development or investment inquiries:
Email: bd@avantibiosciences.com